Rifaximin is an antibiotic medicine. It's used to treat certain types of stomach infections, like those caused by E. coli bacteria. It can also help with a liver condition called hepatic encephalopathy.
Every report comes from a Lived member, sent anonymously.
Have you tried Rifaximin for Liver Cirrhosis?
Rifaximin, sold in the US as Xifaxan, is a prescription antibiotic that acts almost entirely inside the gut. It is approved for three quite different uses, each with its own tablet strength and schedule. The 200 mg tablet treats travelers' diarrhea caused by E. coli bacteria in adults and children 12 and older. It is meant for ordinary watery travelers' diarrhea, not diarrhea that comes with fever or blood in the stool, which is more likely caused by bacteria rifaximin does not reliably treat. The 550 mg tablet is used in adults with advanced liver disease to lower the chance that overt hepatic encephalopathy comes back. Hepatic encephalopathy is a decline in brain function, ranging from confusion, sleepiness and personality changes to coma, that happens when a damaged liver can no longer clear toxins produced by bacteria in the intestine. Rifaximin is usually added to lactulose, a syrup that is the standard first treatment. The 550 mg tablet is also approved for adults with irritable bowel syndrome with diarrhea (IBS-D), a long-term condition of abdominal pain, loose stools and urgency without visible damage to the gut. The American College of Gastroenterology recommends it as a treatment option for overall IBS-D symptoms. Doctors sometimes also prescribe rifaximin off-label for small intestinal bacterial overgrowth (SIBO), where excess bacteria in the small intestine cause bloating and diarrhea; studies suggest it often clears the overgrowth, but they are mostly small and of limited quality.
Rifaximin belongs to the rifamycin family of antibiotics, which also includes rifampin. It blocks the enzyme bacteria use to read their genes and make proteins, so the bacteria stop growing. What sets rifaximin apart is that very little of it is absorbed into the bloodstream. It stays in the intestine and acts on bacteria there, which is why it can be used for gut problems but cannot treat infections elsewhere in the body. In hepatic encephalopathy, reducing toxin-producing gut bacteria means fewer of those substances reach the brain. In IBS-D, the exact reason it helps is not fully understood; changes in the gut's bacterial mix are thought to play a part.
Rifaximin is a tablet taken by mouth, with or without food. The schedule depends on what it is treating. For travelers' diarrhea, it is a short course of 200 mg three times a day for three days. For IBS-D, it is 550 mg three times a day for 14 days; if symptoms return later, the same two-week course can be repeated up to two more times. For hepatic encephalopathy, it is 550 mg twice a day taken every day as ongoing prevention, usually alongside lactulose. Finish a prescribed course even if you feel better early, since skipping doses can make it less effective and encourage resistant bacteria. For travelers' diarrhea, stop rifaximin and get medical care the same day if diarrhea gets worse or lasts more than 24 to 48 hours, or if you develop fever or blood in the stool; a different antibiotic or further testing may be needed.
Most people taking short courses notice few side effects. Headache was the most common complaint in travelers' diarrhea studies, and mild nausea in IBS-D studies, at rates close to placebo. In people with advanced liver disease taking it long term, swelling of the legs, nausea, dizziness, tiredness and itching were reported, though many of these also reflect the liver disease itself. Like nearly all antibiotics, rifaximin can allow C. difficile (Clostridioides difficile), a bacterium that causes severe colon inflammation, to overgrow. Call your clinician promptly if you develop frequent watery or bloody diarrhea, especially with cramps or fever, during treatment or even two months or more after finishing it. Allergic reactions are uncommon but can be serious and can start within minutes of a dose. Swelling of the face or tongue, trouble swallowing or trouble breathing needs emergency help right away. In people with cirrhosis, rare cases of severe skin reactions and of muscle breakdown have been reported; contact your care team promptly about a spreading or blistering rash or unexplained muscle pain.
Do not take rifaximin if you have had an allergic reaction to it or to another rifamycin antibiotic such as rifampin or rifabutin. Because so little is absorbed, rifaximin has fewer drug interactions than many antibiotics, but a few matter. Cyclosporine, an immune-suppressing medicine used after transplants, and similar drugs can raise rifaximin levels in the blood substantially, especially in people with liver disease. Changes in INR (the blood test that guides warfarin dosing) have been reported in people taking warfarin, a blood thinner, so INR is usually checked more closely when rifaximin is started or stopped. People with the most severe liver impairment absorb more of the drug, and it was little studied in the sickest patients, so it is used with extra care there. There are no human data on use in pregnancy, and animal studies showed birth defects, so tell your prescriber if you are pregnant or planning a pregnancy. Whether it passes into breast milk is unknown.
For travelers' diarrhea, rifaximin shortens the illness rather than stopping it instantly. In one trial, diarrhea ended after about a day and a half on average with rifaximin, compared with about two and a half days on placebo. For IBS-D, the effect is meaningful for some people but not most. In the main trials, about 41% of people reported adequate relief in the month after a two-week course, compared with about 31% on placebo. Benefit can last for weeks after the course ends, and when symptoms return, retreatment is an option. It does not cure IBS, and many people combine it with diet changes or other treatments. For hepatic encephalopathy, rifaximin is a long-term medicine. In a six-month trial where most people also took lactulose, 22% of those on rifaximin had another episode, compared with 46% on placebo, and hospital stays for encephalopathy were also less common. A later trial found that rifaximin worked better with lactulose than on its own, so stopping lactulose without guidance is not advised. Ongoing follow-up with the liver team tracks confusion, alertness and overall liver health.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Rifaximin, what you've noticed, or ask the community a question.